What insurance policy changes affect code R50.9?

There are 6 tracked policy changes affecting code R50.9, including updates from Aetna, Colorado Medicaid, Blue Cross Blue Shield of Wyoming. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code R50.9?

Payers that have issued tracked updates for code R50.9 include: Aetna, Colorado Medicaid, Blue Cross Blue Shield of Wyoming.

How do I get notified when code R50.9 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code R50.9. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code R50.9?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

R50.9 Insurance Policy Changes

ICD-10 R50.9 is officially defined as "Fever, unspecified." code R50.9 is referenced in 6 tracked payer policy changes from Aetna, Colorado Medicaid, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code R50.9 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Aug 18, 2026Medium impact
Influenza Rapid Diagnostic Tests (CPB 0476, reviewed 2026-07-24)
Aetna considers the following influenza diagnostic tests medically necessary when results will inform clinical management, antiviral treatment decisions, or infection control measures. These include rapid molecular assays (nucleic acid amplification tests), multiplex molecular assays that detect influenza A, influenza B, SARS-CoV-2, and/or respiratory syncytial virus, standard RT-PCR and other nucleic acid amplification tests, antigen-based rapid influenza diagnostic tests where molecular testing is not immediately available, and direct and indirect immunofluorescence assays when other testing modalities are not available. Confirmatory molecular testing following a negative rapid influenza diagnostic test is medically necessary during periods of high community influenza activity.
Aetna · Identified Aug 14, 2026Medium impact
Single Photon Emission Computed Tomography (SPECT) (CPB 0376, reviewed 2026-05-28)
Aetna's Clinical Policy Bulletin 0376 sets the coverage rules for single photon emission computed tomography (SPECT). Non-cardiac SPECT is considered medically necessary for a list of indications, including osteomyelitis, distinguishing bone from soft tissue infection, pulmonary embolism by SPECT ventilation/perfusion scintigraphy, distinguishing Parkinson's disease from essential tremor using DaTSCAN, localization of abscesses, lymphoma and necrosis differentiation, neuroendocrine tumor diagnosis and staging, presurgical ictal detection of seizure focus in epilepsy in place of PET, and thyroid cancer iodine imaging. SPECT for coronary artery disease diagnosis and prognosis is considered medically necessary, except as outlined in the policy's exclusion criteria. SPECT for a list of other uses, including Alzheimer's disease and dementia, attention deficit/hyperactivity disorder, autism, schizophrenia, stroke, and absolute quantitation of myocardial blood flow, is considered experimental, investigational or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Double Balloon Enteroscopy (CPB 0737, reviewed 2025-11-13)
Aetna considers double balloon enteroscopy medically necessary for dilation of small bowel strictures in Crohn's disease, evaluating suspected small bowel malignancies, evaluating the colon after incomplete colonoscopy, suspected Meckel's diverticulum with an indefinite imaging work-up, obscure GI bleeding with objective evidence of recurrent bleeding, removing entrapped foreign bodies in the small bowel, removing large polyps greater than 10 mm in Peutz-Jeghers syndrome, GI bleeding when the small intestine is the source, and use with ERCP in individuals with surgically altered upper GI anatomy. Aetna considers double balloon enteroscopy experimental, investigational or unproven for other indications, including detection of small bowel neuroendocrine tumors, small bowel varices, treatment of intussusception, treatment of angioectasia (type 1 small bowel vascular lesions), and treatment of post-operative bile leakage after hepaticojejunostomy. Combined double balloon enteroscopy and endoscopic ultrasound for evaluation of Crohn's disease is also considered experimental, investigational or unproven.
Aetna · Identified Aug 12, 2026Medium impact
Onasemnogene Abeparvovec (Zolgensma and Itvisma) (CPB 0953, reviewed 2026-08-10)
Aetna's clinical policy bulletin covers onasemnogene abeparvovec (Zolgensma and Itvisma) for commercial medical plans and requires precertification of all Aetna participating providers and members in applicable plan designs. Aetna considers Zolgensma medically necessary as a single-dose intravenous infusion for spinal muscular atrophy (SMA) when the member is less than 2 years of age, has a genetically confirmed diagnosis with bi-allelic SMN1 variants and 3 or fewer copies of SMN2, and meets the other listed criteria, and considers Itvisma medically necessary as a single intrathecal dose for SMA when the member is 2 to less than 18 years of age, had onset of signs and symptoms at 6 months of age or older, and meets the other listed criteria. Aetna considers both products experimental, investigational, or unproven for all other indications, and considers repeat administration of onasemnogene abeparvovec experimental, investigational, or unproven.
Colorado Medicaid · Identified Jun 20, 2026Medium impact
Health First Colorado (Colorado's Medicaid Program) News and Updates (B2200475 - 02/2022)
The February 2022 Health First Colorado provider bulletin (B2200475) covers several changes. Effective February 1, 2022, claims requiring electronic visit verification (EVV) go through pre-payment review, and claims without the needed EVV records may deny with EOB 3054. The bulletin also describes at-home OTC COVID-19 test billing under HCPCS E1399 with modifier U1 from January 15, 2022, requires the ordering provider's NPI on DMEPOS claims effective July 1, 2022, and notes that 24 physician-administered drug codes became subject to prior authorization effective January 18, 2022.
Blue Cross Blue Shield of Wyoming · Identified Jun 19, 2026Medium impact
NEW! Screening for COVID-19 Diagnosis Guidance
BCBS Wyoming has updated COVID-19 diagnostic testing coding guidance with new ICD-10 codes and clarified coverage rules. The policy specifies that asymptomatic and pre-surgical COVID-19 testing is covered when medically appropriate, but not for return-to-work or surveillance purposes.

Watch R50.9

Get one email when a payer policy names R50.9, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Influenza Rapid Diagnostic Tests (CPB 0476, reviewed 2026-07-24)

Single Photon Emission Computed Tomography (SPECT) (CPB 0376, reviewed 2026-05-28)

Double Balloon Enteroscopy (CPB 0737, reviewed 2025-11-13)

Onasemnogene Abeparvovec (Zolgensma and Itvisma) (CPB 0953, reviewed 2026-08-10)

Health First Colorado (Colorado's Medicaid Program) News and Updates (B2200475 - 02/2022)

NEW! Screening for COVID-19 Diagnosis Guidance

What insurance policy changes affect code R50.9?

Which payers have updated policy for code R50.9?

How do I get notified when code R50.9 policy changes?

Why do payers change policies for code R50.9?